U.S. Markets closed

Selecta Biosciences, Inc. (SELB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.2700-0.0700 (-1.61%)
At close: 4:00PM EDT
4.4300 +0.16 (+3.75%)
After hours: 07:36PM EDT

Selecta Biosciences, Inc.

65 Grove Street
Watertown, MA 02472
United States
617 923 1400

Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Dr. Carsten BrunnCEO, Pres & Director917.02kN/A1971
Dr. Peter G. Traber M.D.Chief Medical Officer587.6kN/A1955
Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D.Co-Founder and Co-Chair of the Scientific Advisory BoardN/AN/AN/A
Ms. Ann K. DonohueVP of Fin., Interim Principal Financial Officer & Principal Accounting OfficerN/AN/A1981
Dr. Lloyd JohnstonCOO and Sr. VP of R&DN/AN/A1968
Dr. Takashi Kei KishimotoChief Scientific OfficerN/AN/A1960
Ms. Kristen BaldwinChief People OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Selecta Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.